Dose‐response effect of eribulin in preclinical models of osteosarcoma by the pediatric preclinical testing consortium

The pediatric preclinical testing program previously demonstrated activity of eribulin in osteosarcoma patient‐derived xenograft (PDX) models. The phase 2 trial in patients with relapsed osteosarcoma failed to meet response endpoints. Eribulin was evaluated in the original and an expanded set of PDX models and tested at multiple dose levels and schedules to evaluate dose‐response. Maximal response was observed at the highest dose, consistent with prior results. The alternative schedule generated similar responses. We demonstrate steep dose‐response for eribulin in osteosarcoma PDX models, implying that any deviation from achievement of effective concentrations may have a significant impact on activity.

[1]  Andrew J. Robles,et al.  Evaluation of Eribulin Combined with Irinotecan for Treatment of Pediatric Cancer Xenografts , 2020, Clinical Cancer Research.

[2]  J. Hainsworth,et al.  A Randomized Phase II Study of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Operable HER2‐negative Breast Cancer , 2019, Clinical breast cancer.

[3]  R. Goldsby,et al.  A phase II study of eribulin in recurrent or refractory osteosarcoma: A report from the Children's Oncology Group , 2018, Pediatric blood & cancer.

[4]  J. Reid,et al.  A phase 1 study of eribulin mesylate (E7389), a novel microtubule‐targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314) , 2018, Pediatric blood & cancer.

[5]  S. Keir,et al.  Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program , 2013, Pediatric blood & cancer.

[6]  T. Mukohara,et al.  Eribulin mesylate in patients with refractory cancers: a Phase I study , 2011, Investigational New Drugs.

[7]  Sarika Jain,et al.  Eribulin Mesylate , 2011, Clinical Cancer Research.

[8]  C. Takimoto,et al.  A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies , 2009, Clinical Cancer Research.

[9]  J. Khan,et al.  Molecular Characterization of the Pediatric Preclinical Testing Panel , 2008, Clinical Cancer Research.

[10]  M. Jordan,et al.  Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase , 2008, Molecular Cancer Therapeutics.

[11]  Joseph Zeidner,et al.  The pediatric preclinical testing program: Description of models and early testing results , 2007, Pediatric blood & cancer.

[12]  Melvin J. Yu,et al.  Induction of Morphological and Biochemical Apoptosis following Prolonged Mitotic Blockage by Halichondrin B Macrocyclic Ketone Analog E7389 , 2004, Cancer Research.

[13]  Joseph P. Near,et al.  How to cite this article , 2011 .